Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 5 | 2019 | 97 | 1.430 |
Why?
|
| Nuclear Medicine | 4 | 2021 | 9 | 1.280 |
Why?
|
| Positron-Emission Tomography | 8 | 2021 | 160 | 1.220 |
Why?
|
| Radiopharmaceuticals | 8 | 2021 | 114 | 1.100 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2021 | 81 | 0.950 |
Why?
|
| Radionuclide Imaging | 6 | 2021 | 166 | 0.900 |
Why?
|
| Internship and Residency | 5 | 2016 | 596 | 0.860 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 10 | 0.840 |
Why?
|
| Chylous Ascites | 1 | 2021 | 11 | 0.830 |
Why?
|
| Diuretics | 1 | 2021 | 96 | 0.780 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 95 | 0.780 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.770 |
Why?
|
| Radiation Exposure | 1 | 2021 | 84 | 0.760 |
Why?
|
| Accreditation | 5 | 2021 | 72 | 0.710 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 2323 | 0.710 |
Why?
|
| Indium Radioisotopes | 3 | 2013 | 19 | 0.620 |
Why?
|
| Radiologists | 1 | 2016 | 35 | 0.560 |
Why?
|
| Tomography, Emission-Computed | 3 | 2007 | 40 | 0.560 |
Why?
|
| Sexism | 1 | 2015 | 11 | 0.550 |
Why?
|
| Sarcoidosis | 2 | 2009 | 77 | 0.530 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 510 | 0.500 |
Why?
|
| Clinical Competence | 2 | 2016 | 657 | 0.500 |
Why?
|
| Fractures, Bone | 2 | 2012 | 132 | 0.440 |
Why?
|
| Quality Improvement | 1 | 2016 | 413 | 0.430 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 62 | 0.430 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 83 | 0.420 |
Why?
|
| Education, Medical, Graduate | 4 | 2019 | 214 | 0.410 |
Why?
|
| Diphosphonates | 1 | 2012 | 39 | 0.410 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 778 | 0.390 |
Why?
|
| Fasting | 1 | 2009 | 75 | 0.350 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 167 | 0.310 |
Why?
|
| Faculty, Medical | 3 | 2019 | 110 | 0.300 |
Why?
|
| Humans | 29 | 2021 | 68525 | 0.290 |
Why?
|
| Gallium Radioisotopes | 2 | 2007 | 5 | 0.290 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2013 | 137 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 300 | 0.260 |
Why?
|
| School Admission Criteria | 2 | 2015 | 36 | 0.250 |
Why?
|
| Musculoskeletal Diseases | 1 | 2004 | 45 | 0.240 |
Why?
|
| Biomedical Research | 2 | 2016 | 310 | 0.210 |
Why?
|
| Octreotide | 1 | 2021 | 21 | 0.210 |
Why?
|
| Paracentesis | 1 | 2021 | 25 | 0.210 |
Why?
|
| Myositis | 1 | 2001 | 24 | 0.210 |
Why?
|
| Technetium Tc 99m Mertiatide | 1 | 2021 | 2 | 0.200 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2021 | 6 | 0.200 |
Why?
|
| Reference Standards | 1 | 2021 | 115 | 0.200 |
Why?
|
| Leadership | 2 | 2019 | 135 | 0.200 |
Why?
|
| Adult | 9 | 2021 | 21375 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2021 | 7264 | 0.190 |
Why?
|
| United States | 6 | 2021 | 7335 | 0.190 |
Why?
|
| Program Development | 2 | 2019 | 240 | 0.190 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 799 | 0.180 |
Why?
|
| Awards and Prizes | 1 | 2019 | 27 | 0.180 |
Why?
|
| Budgets | 1 | 2019 | 12 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1172 | 0.180 |
Why?
|
| Curriculum | 3 | 2016 | 575 | 0.150 |
Why?
|
| Gastric Emptying | 1 | 2017 | 24 | 0.150 |
Why?
|
| Male | 15 | 2021 | 37281 | 0.150 |
Why?
|
| Hydrothorax | 1 | 2016 | 7 | 0.140 |
Why?
|
| Feedback | 1 | 2016 | 90 | 0.140 |
Why?
|
| Students, Medical | 2 | 2016 | 210 | 0.140 |
Why?
|
| Radiography | 2 | 2016 | 572 | 0.140 |
Why?
|
| Peritoneum | 1 | 2016 | 27 | 0.140 |
Why?
|
| Physicians | 1 | 2019 | 324 | 0.140 |
Why?
|
| Competency-Based Education | 1 | 2016 | 32 | 0.140 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 60 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 1753 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 284 | 0.120 |
Why?
|
| Prostate | 2 | 2013 | 116 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2016 | 502 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 621 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2014 | 66 | 0.120 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 13 | 0.120 |
Why?
|
| Middle Aged | 10 | 2021 | 21119 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1039 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2012 | 70 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 306 | 0.110 |
Why?
|
| Cultural Diversity | 1 | 2012 | 67 | 0.110 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2011 | 16 | 0.100 |
Why?
|
| Seminal Vesicles | 1 | 2011 | 7 | 0.100 |
Why?
|
| Breast Implants | 1 | 2011 | 18 | 0.100 |
Why?
|
| Schools, Medical | 1 | 2012 | 157 | 0.100 |
Why?
|
| Female | 8 | 2019 | 38015 | 0.100 |
Why?
|
| Femur | 1 | 2012 | 113 | 0.100 |
Why?
|
| Minority Groups | 1 | 2012 | 196 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 239 | 0.100 |
Why?
|
| Cryosurgery | 1 | 2010 | 53 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2010 | 82 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 274 | 0.090 |
Why?
|
| Subtraction Technique | 1 | 2009 | 12 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2009 | 143 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.080 |
Why?
|
| Aged | 7 | 2014 | 14842 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2008 | 100 | 0.080 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2007 | 9 | 0.080 |
Why?
|
| Job Description | 1 | 2007 | 23 | 0.080 |
Why?
|
| Allied Health Occupations | 1 | 2007 | 11 | 0.080 |
Why?
|
| Technology, Radiologic | 1 | 2006 | 7 | 0.070 |
Why?
|
| Allied Health Personnel | 1 | 2007 | 37 | 0.070 |
Why?
|
| Leukocytes | 1 | 2007 | 99 | 0.070 |
Why?
|
| Credentialing | 1 | 2006 | 23 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2021 | 258 | 0.070 |
Why?
|
| Medicine | 1 | 2006 | 51 | 0.070 |
Why?
|
| Specialization | 1 | 2006 | 66 | 0.070 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 7 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 4843 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 122 | 0.070 |
Why?
|
| Professional Competence | 1 | 2007 | 100 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2006 | 31 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2006 | 110 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 1139 | 0.070 |
Why?
|
| Seminoma | 1 | 2004 | 6 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 119 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 147 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 1 | 2004 | 27 | 0.060 |
Why?
|
| Consumer Behavior | 1 | 2005 | 68 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 206 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 68 | 0.060 |
Why?
|
| Ilium | 1 | 2003 | 16 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2004 | 40 | 0.060 |
Why?
|
| Heart | 1 | 2008 | 850 | 0.060 |
Why?
|
| Prosthesis-Related Infections | 1 | 2004 | 70 | 0.060 |
Why?
|
| Arthroplasty, Replacement | 1 | 2004 | 48 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 201 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2005 | 269 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2005 | 339 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 696 | 0.050 |
Why?
|
| Myocardium | 1 | 2008 | 1204 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 38 | 0.050 |
Why?
|
| Lymphoma | 1 | 2001 | 116 | 0.050 |
Why?
|
| Leg | 1 | 2001 | 191 | 0.050 |
Why?
|
| South Carolina | 3 | 2015 | 2750 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 561 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2004 | 1329 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 193 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 1341 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 403 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2016 | 9 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2006 | 2222 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2016 | 108 | 0.030 |
Why?
|
| Licensure | 1 | 2015 | 18 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 53 | 0.030 |
Why?
|
| Informed Consent | 1 | 2016 | 127 | 0.030 |
Why?
|
| Mentors | 1 | 2015 | 81 | 0.030 |
Why?
|
| Teaching | 1 | 2016 | 169 | 0.030 |
Why?
|
| Career Choice | 1 | 2015 | 98 | 0.030 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 72 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 122 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 254 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 261 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 311 | 0.030 |
Why?
|
| Communication | 1 | 2016 | 329 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 127 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2798 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 191 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2010 | 138 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 349 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 536 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3256 | 0.020 |
Why?
|
| Equipment Design | 1 | 2008 | 500 | 0.020 |
Why?
|
| Diverticulum | 1 | 2006 | 29 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 705 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2005 | 10 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3702 | 0.020 |
Why?
|
| Body Burden | 1 | 2005 | 27 | 0.020 |
Why?
|
| Etoposide | 1 | 2004 | 64 | 0.020 |
Why?
|
| Radiation Protection | 1 | 2005 | 71 | 0.020 |
Why?
|
| Cisplatin | 1 | 2004 | 192 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 539 | 0.010 |
Why?
|
| Health Personnel | 1 | 2006 | 286 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 100 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 150 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 467 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 2004 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 5719 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 8903 | 0.010 |
Why?
|